[Hematopoietic cells raising with plerixafor in non-Hodgkin lymphoma]. / Movilización de células hematopoyéticas con plerixafor en linfoma no Hodgkin folicular.
Rev Med Inst Mex Seguro Soc
; 50(4): 449-51, 2012.
Article
em Es
| MEDLINE
| ID: mdl-23234751
ABSTRACT
BACKGROUND:
bone marrow autologous transplantation (BMAT) has proven benefits in patients treated for non-Hodgkin's lymphoma (NHL). Plerixafor is an inhibitor of CXCR4 receptor. The aim was to report the raise of hematopoietic cells with plerixafor in patients with NHL. CLINICAL CASES patient 1 with follicular NHL, GI, intermediate FLIPI, CD20+, CD45+, BCL-2+, who reached complete response after three chemotherapy regimes. Mobilization failed after use of filgrastim (G-CSF) alone and G-CSF + cyclophosphamide. A new attempt was made with G-CSF + plerixafor (G-CSF, 10 µg/kg for 7 days + plerixafor, 240 µg/kg in days 4 to 7). Patient 2 with follicular NHL and CD20+ reached complete remission with MINE after therapeutic failure with other regimes, but develops severe marrow toxicity. Mobilization was supported with G-CSF 10 µg/kg/d + plerixafor in days 4 and 5. In case one, proper cell counts where obtained after three aphaeresis. In the second case, two harvests add of 2.7 × 106/kg were obtained.CONCLUSIONS:
plerixafor raised the hematopoietic stem cells in peripheral blood and improves mobilization of proper cell population.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Linfoma não Hodgkin
/
Mobilização de Células-Tronco Hematopoéticas
/
Compostos Heterocíclicos
Limite:
Adult
/
Humans
/
Male
Idioma:
Es
Ano de publicação:
2012
Tipo de documento:
Article